glp 1 cardiovascular effects Frontiers 💉 GLP-1's have been FDA

Description

Overall, tirzepatides dual agonism of GLP1 and GIP receptors appears to provide encouraging cardiovascular benefits beyond glycemic control, offering a potential new therapeutic option for treating cardiovascular diseases and heart failure

This may help avoid rapid rises in blood glucose after meals

Researchers seeking a detailed catalogue of the preclinical publications underpinning these findings are directed to the Retatrutide Evidence Dossier

94-100 According to the USPSTF, the evidence supports referring all adults with obesity to intensive, multicomponent behavioral interventions for both weight reduction and weight maintenance

Its central effects are mediated by direct GLP-1 stimulation of anorexigenic neurons (proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) neurons) and inhibition of orexigenic neurons (neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons), located in the arcuate nucleus in the hypothalamus, reducing hunger and increasing satiety